FDA to Convene Expert Panel on Expanding Access to Peptides Amid Safety, Regulatory Debate AJMC FDA Peptide Update: Category 2 Removals Explained An FDA Reversal on Peptides Could Open the Market to Unsafe Drugs ProPublica The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York FDA Compliance for Peptide Therapy and BPC 157 Holt Law